Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Science Translational Medicine

Volumn 9, Issue 385, 2017, Pages

  Schmittnaegel, Martina ^a   Rigamonti, Nicoló ^a,d   Kadioglu, Ece ^a   Cassará, Antonino ^a   Rmili, Céline Wyser ^a   Kiialainen, Anna ^b   Kienast, Yvonne ^c   Mueller, Hans Joachim ^c   Ooi, Chia Huey ^b,c   Laoui, Damya ^a   De Palma, Michele ^a  

^a SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d MOLECULAR PARTNERS AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN 2 ANTIBODY; BISPECIFIC ANTIBODY; CD8 ANTIGEN; GAMMA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; CD274 PROTEIN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG TARGETING; ENDOTHELIUM CELL; EXTRAVASATION; GENETIC ENGINEERING; IMMUNOCOMPETENT CELL; MELANOMA; METASTATIC BREAST CANCER; MOUSE; NONHUMAN; PANCREAS ISLET CELL TUMOR; PERIVASCULAR SPACE; PHAGOCYTE; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; BLOOD VESSEL; C57BL MOUSE; CD8+ T LYMPHOCYTE; GENETICS; METABOLISM; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANGIOPOIETIN-2; ANIMALS; ANTIGENS, CD274; BLOOD VESSELS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROGRAMMED CELL DEATH 1 RECEPTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85017547813     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aak9670     Document Type: Article

References (66)

1. J. Folkman, K. Watson, D. Ingber, D. Hanahan, Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61 (1989).
2. N. Ferrara, A. P. Adamis, Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15, 385-403 (2016).
3. K. J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H. S. Phillips, N. Ferrara, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
4. G. Bergers, D. Hanahan, Modes of resistance to anti-Angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
5. M. De Palma, D. Hanahan, The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities. Mol. Oncol. 6, 111-127 (2012).
6. R. Mazzieri, F. Pucci, D. Moi, E. Zonari, A. Ranghetti, A. Berti, L. S. Politi, B. Gentner, J. L. Brown, L. Naldini, L. Naldini, M. De Palma, Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19, 512-526 (2011).
7. N. Rigamonti, E. Kadioglu, I. Keklikoglou, C. W. Rmili, C. C. Leow, M. De Palma, Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 8, 696-706 (2014).
8. T. Holopainen, P. Saharinen, G. D'Amico, A. Lampinen, L. Eklund, R. Sormunen, A. Anisimov, G. Zarkada, M. Lohela, H. Heloterä, T. Tammela, L. E. Benjamin, S. Ylä-Herttuala, C. C. Leow, G. Y. Koh, K. Alitalo, Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J. Natl. Cancer Inst. 104, 461-475 (2012).
9. H. Hashizume, B. L. Falcón, T. Kuroda, P. Baluk, A. Coxon, D. Yu, J. V. Bready, J. D. Oliner, D. M. McDonald, Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 70, 2213-2223 (2010).
10. A. Scholz, P. N. Harter, S. Cremer, B. H. Yalcin, S. Gurnik, M. Yamaji, M. Di Tacchio, K. Sommer, P. Baumgarten, O. Bähr, J. P. Steinbach, J. Trojan, M. Glas, U. Herrlinger, D. Krex, M. Meinhardt, A. Weyerbrock, M. Timmer, R. Goldbrunner, M. Deckert, C. Braun, J. Schittenhelm, J. T Frueh, E. Ullrich, M. Mittelbronn, K. H. Plate, Y. Reiss, Endothelial cellderived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumabresistant glioblastoma. EMBO Mol. Med. 8, 39-57 (2015).
11. C. Daly, A. Eichten, C. Castanaro, E. Pasnikowski, A. Adler, A. S. Lalani, N. Papadopoulos, A. H. Kyle, A. I. Minchinton, G. D. Yancopoulos, G. Thurston, Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 73, 108-118 (2013).
12. Y. Kienast, C. Klein, W. Scheuer, R. Raemsch, E. Lorenzon, D. Bernicke, F. Herting, S. Yu, H. H. The, L. Martarello, C. Gassner, K.-G. Stubenrauch, K. Munro, H. G. Augustin, M. Thomas, Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin. Cancer Res. 19, 6730-6740 (2013).
13. M. Thomas, Y. Kienast, W. Scheuer, M. Bähner, K. Kaluza, C. Gassner, F. Herting, U. Brinkmann, S. Seeber, A. Kavlie, M. Welschof, S. Ries, K. M. Weidner, J. T. Regula, C. Klein, A novel angiopoietin-2 selective fully human antibody with potent anti-Tumoral and anti-Angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. PLOS ONE 8, e54923 (2013).
14. J.-S. Park, I.-K. Kim, S. Han, I. Park, C. Kim, J. Bae, S. J. Oh, S. Lee, J. H. Kim, D.-C. Woo, Y. He, H. G. Augustin, I. Kim, D. Lee, G. Y. Koh, Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell 30, 953-967 (2016).
15. K. Srivastava, J. Hu, C. Korn, S. Savant, M. Teichert, S. S. Kapel, M. Jugold, E. Besemfelder, M. Thomas, M. Pasparakis, H. G. Augustin, Postsurgical adjuvant tumor therapy by combining anti-Angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 26, 880-895 (2014).
16. J. F. A. P. Miller, M. Sadelain, The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 27, 439-449 (2015).
17. P. Sharma, J. P. Allison, The future of immune checkpoint therapy. Science 348, 56-61 (2015).
18. A. K. Palucka, L. M. Coussens, The basis of oncoimmunology. Cell 164, 1233-1247 (2016).
19. Y. Huang, S. Goel, D. G. Duda, D. Fukumura, R. K. Jain, Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 73, 2943-2948 (2013).
20. E. Lanitis, M. Irving, G. Coukos, Targeting the tumor vasculature to enhance T cell activity. Curr. Opin. Immunol. 33, 55-63 (2015).
21. G. T. Motz, G. Coukos, The parallel lives of angiogenesis and immunosuppression: Cancer and other tales. Nat. Rev. Immunol. 11, 702-711 (2011).
22. P. E. Hughes, S. Caenepeel, L. C. Wu, Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol. 37, 462-476 (2016).
23. J. Kloepper, L. Riedemann, Z. Amoozgar, G. Seano, K. Susek, V. Yu, N. Dalvie, R. L. Amelung, M. Datta, J. W. Song, V. Askoxylakis, J. W. Taylor, C. Lu-Emerson, A. Batista, N. D. Kirkpatrick, K. Jung, M. Snuderl, A. Muzikansky, K. G. Stubenrauch, O. Krieter, H. Wakimoto, L. Xu, L. L. Munn, D. G. Duda, D. Fukumura, T. T. Batchelor, R. K. Jain, Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-Tumor phenotype and prolongs glioblastoma survival. Proc. Natl. Acad. Sci. U.S.A. 113, 4476-4481 (2016).
24. T. Yamazaki, H. Akiba, A. Koyanagi, M. Azuma, H. Yagita, K. Okumura, Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-g-induced nitric oxide production. J. Immunol. 175, 1586-1592 (2005).
25. W. C. Liang, X. Wu, F. V. Peale, C. V. Lee, Y. G. Meng, J. Gutierrez, L. Fu, A. K. Malik, H.-P. Gerber, N. Ferrara, G. Fuh, Cross-species vascular endothelial growth factor (VEGF)- blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281, 951-961 (2006).
26. E. Y. Lin, J. G. Jones, P. Li, L. Zhu, K. D. Whitney, W. J. Muller, J. W. Pollard, Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163, 2113-2126 (2003).
27. A. W. Lund, F. V. Duraes, S. Hirosue, V. R. Raghavan, C. Nembrini, S. N. Thomas, A. Issa, S. Hugues, M. A. Swartz, VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep. 1, 191-199 (2012).
28. C. Baer, M. L. Squadrito, D. Laoui, D. Thompson, S. K. Hansen, A. Kiialainen, S. Hoves, C. H. Ries, C.-H. Ooi, M. De Palma, Suppression of microRNA activity amplifies IFN-g-induced macrophage activation and promotes anti-Tumour immunity. Nat. Cell Biol. 18, 790-802 (2016).
29. P. Nasarre, M. Thomas, K. Kruse, I. Helfrich, V. Wolter, C. Deppermann, D. Schadendorf, G. Thurston, U. Fiedler, H. G. Augustin, Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 69, 1324-1333 (2009).
30. R. K. Jain, Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26, 605-622 (2014).
31. K. Palucka, J. Banchereau, Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12, 265-277 (2012).
32. D. Hanahan, L. M. Coussens, Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
33. A. Sica, V. Bronte, Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155-1166 (2007).
34. S. Spranger, R. M. Spaapen, Y. Zha, J. Williams, Y. Meng, T. T. Ha, T. F. Gajewski, Upregulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).
35. E. Allen, A. Jabouille, L. B. Rivera, I. Lodewijckx, R. Missiaen, V. Steri, K. Feyen, J. Tawney, D. Hanahan, I. P. Michael, G. Bergers, Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 9, eaak9679 (2017).
36. G. Jimenez-Valerio, O. Casanovas, Antiangiogenic resistance via metabolic symbiosis. Mol. Cell. Oncol. 3, e1211979 (2016).
37. E. A. Kuczynski, R. S. Kerbel, Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. Chin. J. Cancer 35, 97 (2016).
38. S. Frentzas, E. Simoneau, V. L. Bridgeman, P. B. Vermeulen, S. Foo, E. Kostaras, M. R. Nathan, A. Wotherspoon, Z.-h. Gao, Y. Shi, G. Van den Eynden, F. Daley, C. Peckitt, X. Tan, A. Salman, A. Lazaris, P. Gazinska, T. J Berg, Z. Eltahir, L. Ritsma, J. van Rheenen, A. Khashper, G. Brown, H. Nyström, M. Sund, S. Van Laere, E. Loyer, L. Dirix, D. Cunningham, P. Metrakos, A. R. Reynolds, Vessel co-option mediates resistance to anti-Angiogenic therapy in liver metastases. Nat. Med. 22, 1294-1302 (2016).
39. J. Holash, P. C. Maisonpierre, D. Compton, P. Boland, C. R. Alexander, D. Zagzag, G. D. Yancopoulos, S. J. Wiegand, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998 (1999).
40. J. H. Im, T. Tapmeier, L. Balathasan, A. Gal, S. Yameen, S. Hill, S. Smart, O. Noterdaeme, M. Kelly, M. Brady, W. Fu, K. Kruse, E. J. Bernhard, H. G. Augustin, R. J. Muschel, G-CSF rescues tumor growth and neo-Angiogenesis during liver metastasis under host angiopoietin-2 deficiency. Int. J. Cancer 132, 315-326 (2013).
41. A. E. M. Dirkx, M. G. A. oude Egbrink, M. J. E. Kuijpers, S. T. van der Niet, V. V. T. Heijnen, J. C. A. Bouma-Ter Steege, J. Wagstaff, A. W. Griffioen, Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 63, 2322-2329 (2003).
42. G. T. Motz, S. P. Santoro, L.-P. Wang, T. Garrabrant, R. R. Lastra, I. S. Hagemann, P. Lal, M. D. Feldman, F. Benencia, G. Coukos, Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607-615 (2014).
43. R. J. Buckanovich, A. Facciabene, S. Kim, F. Benencia, D. Sasaroli, K. Balint, D. Katsaros, A. O'Brien-Jenkins, P. A Gimotty, G. Coukos, Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14, 28-36 (2008).
44. D. I. Gabrilovich, H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh, D. P. Carbone, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096-1103 (1996).
45. D. Gabrilovich, T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf, D. P. Carbone, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150-4166 (1998).
46. J. J. Wallin, J. C. Bendell, R. Funke, M. Sznol, K. Korski, S. Jones, G. Hernandez, J. Mier, X. He, F. S. Hodi, M. Denker, V. Leveque, M. Cañamero, G. Babitski, H. Koeppen, J. Ziai, N. Sharma, F. Gaire, D. S. Chen, D. Waterkamp, P. S. Hegde, D. F. McDermott, Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7, 12624 (2016).
47. F. S. Hodi, D. Lawrence, C. Lezcano, X. Wu, J. Zhou, T. Sasada, W. Zeng, A. Giobbie-Hurder, M. B. Atkins, N. Ibrahim, P. Friedlander, K. T. Flaherty, G. F. Murphy, S. Rodig, E. F. Velazquez, M. C. Mihm Jr., S. Russell, P. J. DiPiro, J. T. Yap, N. Ramaiya, A. D. Van den Abbeele, M. Gargano, D. McDermott, Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2, 632-642 (2014).
48. T. Osada, G. Chong, R. Tansik, T. Hong, N. Spector, R. Kumar, H. I. Hurwitz, I. Dev, A. B. Nixon, H. K. Lyerly, T. Clay, M. A. Morse, The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57, 1115-1124 (2008).
49. A. Scholz, V. Lang, R. Henschler, M. Czabanka, P. Vajkoczy, E. Chavakis, J. Drynski, P. N. Harter, M. Mittelbronn, D. J. Dumont, K. H. Plate, Y. Reiss, Angiopoietin-2 promotes myeloid cell infiltration in a b2-integrin-dependent manner. Blood 118, 5050-5059 (2011).
50. A. Scholz, K. H. Plate, Y. Reiss, Angiopoietin-2: A multifaceted cytokine that functions in both angiogenesis and inflammation. Ann. N. Y. Acad. Sci. 1347, 45-51 (2015).
51. S. B. Coffelt, Y.-Y. Chen, M. Muthana, A. F. Welford, A. O. Tal, A. Scholz, K. H. Plate, Y. Reiss, C. Murdoch, M. De Palma, C. E. Lewis, Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J. Immunol. 186, 4183-4190 (2011).
52. A. S. Harney, E. N. Arwert, D. Entenberg, Y. Wang, P. Guo, B.-Z. Qian, M. H. Oktay, J. W. Pollard, J. G. Jones, J. S. Condeelis, Real-Time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov. 5, 932-943 (2015).
53. E. Kadioglu, M. De Palma, Cancer metastasis: Perivascular macrophages under watch. Cancer Discov. 5, 906-908 (2015).
54. Z. Qin, J. Schwartzkopff, F. Pradera, T. Kammertoens, B. Seliger, H. Pircher, T. Blankenstein, A critical requirement of interferon g-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 63, 4095-4100 (2003).
55. J. Choi, D. R. Enis, K. P. Koh, S. L. Shiao, J. S. Pober, T lymphocyte-endothelial cell interactions. Annu. Rev. Immunol. 22, 683-709 (2004).
56. J. Schoenfeld, M. Jinushi, Y. Nakazaki, D. Wiener, J. Park, R. Soiffer, D. Neuberg, M. Mihm, F. S. Hodi, G. Dranoff, Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 70, 10150-10160 (2010).
57. X. Wu, A. Giobbie-Hurder, X. Liao, C. Connelly, E. M. Connolly, J. Li, M. P. Manos, D. Lawrence, D. McDermott, M. Severgnini, J. Zhou, E. Gjini, A. Lako, M. Lipschitz, C. J. Pak, S. Abdelrahman, S. Rodig, F. S. Hodi, Angiopoietin-2 as a biomarker and target for immune checkpoint therapy. Cancer Immunol. Res. 5, 17-28 (2017).
58. L. B. Rivera, G. Bergers, Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol. 36, 240-249 (2015).
59. A. Johansson, J. Hamzah, R. Ganss, More than a scaffold: Stromal modulation of tumor immunity. Biochim. Biophys. Acta 1865, 3-13 (2016).
60. X. D. Liu, A. Hoang, L. Zhou, S. Kalra, A. Yetil, M. Sun, Z. Ding, X. Zhang, S. Bai, P. German, P. Tamboli, P. Rao, J. A. Karam, C. Wood, S. Matin, A. Zurita, A. Bex, A. W. Griffioen, J. Gao, P. Sharma, N. Tannir, K. Sircar, E. Jonasch, Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol. Res. 3, 1017-1029 (2015).
61. L. B. Rivera, D. Meyronet, V. Hervieu, M. J. Frederick, E. Bergsland, G. Bergers, Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep. 11, 577-591 (2015).
62. K. Kim, A. D. Skora, Z. Li, Q. Liu, A. J. Tam, R. L. Blosser, L. A. Diaz Jr., N. Papadopoulos, K. W. Kinzler, B. Vogelstein, S. Zhou, Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. U.S.A. 111, 11774-11779 (2014).
63. W. Peng, C. Liu, C. Xu, Y. Lou, J. Chen, Y. Yang, H. Yagita, W. W. Overwijk, G. Lizée, L. Radvanyi, P. Hwu, PD-1 blockade enhances T-cell migration to tumors by elevating IFN-g inducible chemokines. Cancer Res. 72, 5209-5218 (2012).
64. D. G. McFadden, K. Politi, A. Bhutkar, F. K. Chen, X. Song, M. Pirun, P. M. Santiago, C. Kim-Kiselak, J. T. Platt, E. Lee, E. Hodges, A. P. Rosebrock, R. T. Bronson, N. D. Socci, G. J. Hannon, T. Jacks, H. Varmus, Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 113, E6409-E6417 (2016).
65. C. A. Santa-Maria, W. J. Gradishar, Changing treatment paradigms in metastatic breast cancer: Lessons learned. JAMA Oncol. 1, 528-534 (2015).
66. J. Stagg, B. Allard, Immunotherapeutic approaches in triple-negative breast cancer: Latest research and clinical prospects. Ther. Adv. Med. Oncol. 5, 169-181 (2013).